Response to zolpidem in oromandibular dystonia: A case report

Martínez-Ramírez, Daniel; Paz-Gomez, Viviana; Rodríguez, Ramón

doi:10.1016/j.parkreldis.2014.11.006

Cited by 12 publications

(11 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tetrabenazine reported benefits in the treatment of the symptoms in 26 to 60% of OMDy patients but is frequently associated with important side effects like parkinsonism and suicidal ideation [7,53]. Zolpidem in doses ranging from 5 to 20 mg has shown some promising results, but since these findings are only in a relatively small number of cases, prospective clinical trials are needed to determine its effectiveness [54,55].…”

Section: Treatment Approachesmentioning

confidence: 99%

Orofacial Dystonia and Other Oromandibular Movement Disorders

Skármeta¹,

Espinoza-Mellado²,

PedroChana³

2018

Dystonia - Different Prospects

View full text Add to dashboard Cite

Orofacial movement disorders (OMD) are a group of conditions that affect the motor aspect of the trigeminal, facial, and hypoglossal cranial nerves. These alterations are produced by pathologic disorders affecting the central nervous system, manifesting as isolated or combined hyperkinetic dysfunctional activities on the masticatory, facial mimic, or tongue musculatures. A comprehensive understanding of orofacial dystonias is essential to identify different variants of OMD that could be easily mislabeled or misdiagnosed. In this chapter, the authors focus on different aspects of the pathophysiology, epidemiology, clinical features, and management of orofacial dystonias and other movement disorders that are poorly recognized but not uncommon presentations of OMD, such as orofacial dyskinesias, drug-induced orofacial reactions, tardive orofacial syndromes, and bruxism.

show abstract

Section: Treatment Approachesmentioning

confidence: 99%

Orofacial Dystonia and Other Oromandibular Movement Disorders

Skármeta¹,

Espinoza-Mellado²,

PedroChana³

2018

Dystonia - Different Prospects

View full text Add to dashboard Cite

show abstract

“…Orofacial/oromandibular dystonia typically responds poorly to oral medications, although there are recent reports that zolpidem may be helpful. 60 There are emerging reports of DBS for OMD, usually targeted to the globus pallidus internus. 61,62 Abnormal facial movements can respond well to DBS; the effect on speech and swallowing is more variable.…”

Section: Approaches To Treatmentmentioning

confidence: 99%

Botulinum Toxin Treatment of Blepharospasm, Orofacial/Oromandibular Dystonia, and Hemifacial Spasm

Karp

Alter

2016

Semin Neurol

View full text Add to dashboard Cite

Blepharospasm is a focal dystonia characterized by involuntary, repetitive eye closure. Orofacial and oromandibular dystonia describe involuntary dystonic movements of orofacial and oromandibular musculature. Hemifacial spasm is characterized by repetitive synchronous contraction of facial nerve innervated muscles on one side of the face. In this article, the clinical presentation, epidemiology, and approaches to treatment are reviewed. Technical aspects of using botulinum toxin for treatment and reported outcomes are discussed.

show abstract

“…4 OMD most frequently affects the muscles of mastication or the tongue muscles, causing involuntary jaw opening, closing, deviation, or tongue thrust, among others. [4][5][6] In some cases, OMD may occur concomitantly with dystonia of other areas, as in the case of Meige syndrome, which consists of dystonia of the ocular and facial muscles. 2,7,8 OMD is more common among women, with incidence estimates around 6.9 per 100,000 persons in the United States.…”

Section: Introductionmentioning

confidence: 99%

“…16 OMD has no known cure and is most effectively treated conservatively through physical and speech therapy, massage, biofeedback, acupuncture, and fabrication of occlusal appliances. 1,6,11,17 Sensory tricks, including pressure against the dystonic muscle (Le Geste Antagoniste), posturing, speaking, and chewing, have been found to have beneficial long-term effects. 2,5 Although not definitively proven, occlusal appliance use is thought to work similarly by counteracting the dystonic contraction of affected muscles.…”

Section: Introductionmentioning

confidence: 99%

“…Anticholinergics, including benztropine mesylate, currently boast the highest reported success rate. 1,3,5,6,8,10,11,18,19 The use of botulinum toxin (BTX) injections is well established in the treatment of laryngeal and cervical dystonia and has also been studied in OMD, where most commonly botulinum toxin type A (Botox, Allergan Phar-maceuticals Ireland, Dublin, Ireland) is used. 20 BTX injection is hypothesized to influence the pathophysiology of dystonia and currently represents the first line of treatment for OMD.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The American Academy of Oral Medicine Clinical Practice Statement: Oromandibular dystonia

Stoopler

2018

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

View full text Add to dashboard Cite

that oromandibular dystonia (also referred to as orofacial dystonia) is a movement disorder causing paroxysmal or sustained contraction of the affected facial muscles. Oromandibular dystonia may occur alone or as a part of a segmental or generalized dystonia and may be idiopathic or secondary to previous medication or drug use, trauma, or neurodegenerative disease. The AAOM also affirms that patients with suspected oromandibular dystonia should be referred to the appropriate oral and/or medical health care provider(s) for comprehensive evaluation and management of the condition. Management of oromandibular dystonia may include conservative therapies, medications, botulinum toxin injections, or peripheral or central surgical approaches. This Clinical Practice Statement was developed as an educational tool on the basis of expert consensus of the American Academy of Oral Medicine (AAOM) leadership. Readers are encouraged to consider the recommendations in the context of their specific clinical situation and to consult, when appropriate, other sources of clinical, scientific, or regulatory information before making a treatment decision.

show abstract

Response to zolpidem in oromandibular dystonia: A case report

Cited by 12 publications

References 5 publications

Orofacial Dystonia and Other Oromandibular Movement Disorders

Orofacial Dystonia and Other Oromandibular Movement Disorders

Botulinum Toxin Treatment of Blepharospasm, Orofacial/Oromandibular Dystonia, and Hemifacial Spasm

The American Academy of Oral Medicine Clinical Practice Statement: Oromandibular dystonia

Contact Info

Product

Resources

About